You are here

Article info

Article menu

Download PDFPDF

Case Report
Acute visual loss after ipilimumab treatment for metastatic melanoma

Authors

  • Melissa A. Wilson Division of Hematology/Oncology, Department of MedicineUniversity of Pennsylvania Philadelphia PA USA Present address: Division of Hematology and Medical Oncology, Laura and Isaac Perlmutter Cancer CenterNYU Langone Medical Center New York NY USA PubMed articlesGoogle scholar articles
  • Kelly Guld Department of MedicineUniversity of Pennsylvania Philadelphia PA USA Present address: Department of CardiologyUCSF Medical Center San Francisco CA USA PubMed articlesGoogle scholar articles
  • Steven Galetta Department of NeurologyNYU Langone Medical Center New York NY USA PubMed articlesGoogle scholar articles
  • Ryan D. Walsh Departments of Ophthalmology and NeurologyMedical College of Wisconsin Milwaukee WI USA PubMed articlesGoogle scholar articles
  • Julia Kharlip Division of Endocrinology, Department of MedicineUniversity of Pennsylvania Philadelphia PA USA PubMed articlesGoogle scholar articles
  • Madhura Tamhankar Department of Ophthalmology, Scheie Eye InstituteUniversity of Pennsylvania Health System Philadelphia PA USA PubMed articlesGoogle scholar articles
  • Suzanne McGettigan Division of Hematology/Oncology, Department of MedicineUniversity of Pennsylvania Philadelphia PA USA PubMed articlesGoogle scholar articles
  • Lynn M. Schuchter Division of Hematology/Oncology, Department of MedicineUniversity of Pennsylvania Philadelphia PA USA PubMed articlesGoogle scholar articles
  • Leslie A. Fecher Division of Hematology/Oncology, Department of MedicineUniversity of Pennsylvania Philadelphia PA USA Present address: Division of Hematology/Oncology, Department of Internal MedicineUniversity of Michigan C366 MIB 1500 E. Medical Center Drive, SPC5848 48109 Ann Arbor MI USA PubMed articlesGoogle scholar articles

Citation

Wilson MA, Guld K, Galetta S, et al
Acute visual loss after ipilimumab treatment for metastatic melanoma
Journal for ImmunoTherapy of Cancer 2016;4:66. doi: 10.1186/s40425-016-0170-9
Online issue publication 
October 18, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.